Glucotrack, Inc.
Glucotrack, Inc. is a U.S.-based medical device developer focused on novel diabetes technologies. Its core program is the Glucotrack CBGM, an implantable continuous blood glucose monitor being developed for people with Type 1 diabetes and insulin-dependent Type 2 diabetes.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueThe Glucotrack CBGM and related implantable continuous blood glucose monitoring technology for diabetes care.
Clinical trial execution, testing, and development activities needed to advance the device toward commercialization.
Work supporting FDA registration, documentation, and product approval preparation.
Internal research, design, and engineering for new CBGM models and product candidates.
Customers
Glucotrack does not yet appear to have commercial customers because the CBGM has not been commercialized. Its eventual buyers are expected to be people with diabetes, especially Type 1 patients and insulin-dependent Type 2 patients, likely through healthcare providers and reimbursement channels. The company’s near-term stakeholders are clinical investigators, regulators, and financing partners that support development.
Future end users of the implantable CBGM who need continuous glucose data for insulin management.
Future end users who may benefit from continuous monitoring to improve glycemic control.
Hospitals, investigators, and regulators involved in trials, validation, and FDA registration.
Equity and debt investors funding development before commercialization.
Strategy
The company’s strategy is to advance the Glucotrack CBGM through clinical development, FDA registration, and eventual commercialization. Near term, management is focused on preserving liquidity, raising capital, and funding the next stages of development while expanding clinical trial activity and product iterations.
Clinical evidence is required to support regulatory approval and future adoption.
Regulatory clearance is the gate to commercialization and revenue generation.
The company is a going concern and needs external funding to continue operations.
Geography
Glucotrack is headquartered in the United States and its filings are on a U.S. reporting basis. The business currently appears centered on U.S.-based R&D, clinical, and regulatory work, with no disclosed commercial geographic revenue mix because the product has not been commercialized. Geography matters mainly through U.S. FDA oversight, domestic financing access, and the location of clinical development activities.
Risks
Glucotrack faces classic pre-commercial medtech risks: it has not yet generated product revenue, needs significant additional funding, and depends on successful clinical and regulatory execution. The company also disclosed substantial doubt about its ability to continue as a going concern, making financing availability a central business risk.
- Going concern and liquidity shortfallImpact: CriticalLikelihood: High
The company states current cash is not sufficient for the next twelve months and it needs external financing.
Exposure - Clinical and regulatory execution riskImpact: HighLikelihood: High
Commercialization depends on successful trials and FDA registration, both of which can be delayed or fail.
Exposure: Glucotrack CBGM development timeline
- Financing and dilution riskImpact: HighLikelihood: High
The company plans to fund operations through debt or equity, which may be unavailable or dilutive.
Exposure: Shareholders and capital structure
- Commercial adoption riskImpact: MediumLikelihood: High
Even after approval, the implantable device must win physician and patient acceptance versus existing monitoring options.
Exposure: Future revenue conversion
Accounting
Judgemental itemsThe company says other income/expense includes changes in fair value of derivative liabilities, which can create volatility.
Impact: Can materially swing quarterly net loss
Personnel-related expenses in R&D and G&A include stock-based compensation, affecting operating expense levels.
Impact: Raises reported operating costs without cash outflow
Management must assess whether available cash is sufficient and disclose substantial doubt when it is not.
Impact: Affects financial statement presentation and investor risk assessment
Recent financing activity includes convertible notes and warrant exchanges, which can require complex classification and valuation judgments.
Impact: Can affect equity, liabilities, and financing expense
Similar listed companies
Publicly listed companies with a comparable business focus.
DexCom, Inc
DXCM · Surgical & Medical Instruments & Apparatus
DexCom is a U.S.
Senseonics Holdings, Inc.
SENS · Industrial Instruments For Measurement, Display, and Control
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Tandem Diabetes Care, Inc
TNDM · Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy.
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
Alr Technologies SG Ltd.
ALRTF · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026